Vertex Pharmaceuticals traded at $292.55 this Friday June 24th, increasing $9.05 or 3.19 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 8.02 percent. Over the last 12 months, its price rose by 50.54 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 284.68 by the end of this quarter and at 262.32 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
292.55
Daily Change
3.19%
Yearly
50.54%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 152.34 2.89 1.93% 34.84%
Acadia Pharmaceuticals 14.98 0.26 1.77% -42.76%
Acorda Therapeutics 0.52 -0.04 -7.13% -89.91%
Agios Pharmaceuticals 22.57 1.29 6.06% -60.21%
Alnylam Pharmaceuticals 147.50 1.20 0.82% -15.90%
Amgen 245.37 2.28 0.94% 1.11%
Arrowhead Research 34.46 0.20 0.58% -61.85%
Biogen 211.93 0.55 0.26% -39.09%
Bluebird Bio 4.40 0.12 2.80% -85.77%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Bristol-Myers Squibb 78.96 1.27 1.63% 18.31%
Gilead Sciences 63.08 0.50 0.80% -7.07%
Intercept Pharmaceuticals 13.56 0.03 0.22% -38.53%
Incyte Corp 78.19 3.41 4.56% -9.95%
Insmed 21.42 1.57 7.91% -25.98%
Ionis Pharmaceuticals 39.25 0.23 0.59% 0.82%
J&J 182.29 2.63 1.46% 11.01%
Merck & Co 93.13 1.13 1.23% 20.63%
Moderna Inc 144.27 1.01 0.71% -34.40%
Neurocrine Biosciences 98.24 0.84 0.86% -2.04%
Novartis 80.60 2.37 3.03% -4.80%
Puma Biotechnology 2.85 -0.05 -1.72% -70.41%
Pfizer 51.59 1.50 2.99% 32.35%
PTC Therapeutics 40.22 0.11 0.27% -8.30%
Ultragenyx Pharmaceutical 60.57 0.58 0.97% -35.45%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Roche Holding 318.80 12.50 4.08% -7.54%
Sanofi 100.56 4.81 5.02% 13.95%
Seattle Genetics 179.33 5.33 3.06% 14.09%
Sangamo BioSciences 4.31 -0.06 -1.37% -64.14%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
United Therapeutics 238.95 -1.91 -0.79% 32.75%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%

Indexes Price Day Year
US500 3912 116.01 3.06% -8.62%
USND 11608 375.43 3.34% -19.17%
US400 2334 80.04 3.55% -14.38%
USNDX 12106 408.17 3.49% -15.61%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.